Pollen Allergy Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Pollen Allergy Epidemiology Forecast Report Coverage

Expert Market Research's “Pollen Allergy Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of pollen allergy. It projects the future incidence and prevalence rates of pollen allergy cases across various populations. The study covers age, gender, and type as major determinants of the pollen allergy population. The report highlights patterns in the prevalence of pollen allergy over time and projects future trends based on multiple variables.

Pollen Allergy Understanding: Disease Overview

Pollen allergy, commonly referred to as seasonal allergic rhinitis or hay fever, is an immune-mediated condition triggered by exposure to airborne pollen from trees, grasses, and weeds. It occurs when the immune system mistakenly identifies harmless pollen as a threat, leading to the release of histamine and other inflammatory mediators. Symptoms include sneezing, nasal congestion, runny nose, itchy eyes, and throat irritation. The condition is typically classified into seasonal allergic rhinitis, associated with specific pollen periods, and perennial allergic rhinitis, where symptoms persist due to multiple allergens.

Pollen Allergy Epidemiology Perspective

The pollen allergy epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the pollen allergy epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for pollen allergy and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Yi-Bo Hou et al., 2024, pollen allergy shows significant global variation, affecting over 11% of the population in Europe and 18.5% in China, with Artemisia-related prevalence ranging from 10–14% in Europe and exceeding 50% in high-risk regions.
• As per Bhargavi S et al., 2024, incidence within a clinical setting showed 60 confirmed cases out of 750 screened patients, indicating concentrated seasonal occurrence between May and October, with occupational exposure such as housewives (28.33%) and students (30%) contributing notably.
• According to Bhargavi S et al., 2024, age-wise distribution highlights peak prevalence in the 35–60 years group (46.66%), while elderly populations above 60 years show minimal incidence (1.6%), suggesting higher susceptibility during active working years.
• As per Bhargavi S et al., 2024, gender-based analysis indicates a higher proportion of females (56.66%) compared to males (43.33%), reflecting possible biological susceptibility or differential environmental exposure patterns in pollen allergic rhinitis.
• According to Tomoyuki Kiguchi et al., 2025, adolescent prevalence reached 54.4%, with 11.2% experiencing pollen–food allergy syndrome; additionally, Alisa Arens et al., 2025 reported rising sensitization trends, including birch pollen allergy increasing from 11.6% to 31%, with negligible mortality but high seasonal morbidity.

Read more about this report - Request a Free Sample

Country-wise Pollen Allergy Epidemiology

The pollen allergy epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the regions covered in the report, pollen allergy exhibits significant variation in prevalence and impact. In Germany, an estimated 20–30 million people are affected as per Karl-Christian Bergmann et al., 2023. In Spain, 48.7% of patients allergic to Platanus pollen in the Community of Madrid suffer from asthma, reflecting broader trends among pollen-allergic patients as per Javier Chico-Fernández et al., 2025. In India, 10–40% of the population experiences pollen allergy, with 20% of allergies in Bengaluru caused by pollens such as Parthenium, Amaranthus spinosus, Prosopis juliflora, and Ricinus communis, according to Bhargavi S. et al., 2024. These data highlight a varied but substantial epidemiological burden globally.

Pollen Allergy: Treatment Overview

Pollen allergy management focuses on symptom control and reducing allergen exposure. Pharmacological treatments include antihistamines to relieve sneezing and itching, intranasal corticosteroids to reduce inflammation, and decongestants for nasal blockage. Leukotriene receptor antagonists may also be used in certain cases. Allergen immunotherapy, administered as subcutaneous injections or sublingual tablets, is recommended for long-term desensitization. Non-pharmacological measures include avoiding outdoor exposure during high pollen counts, using air purifiers, and wearing masks. Early diagnosis and personalized treatment plans improve patient outcomes and quality of life.

Key Questions Answered

• What are the key findings of pollen allergy epidemiology in the 8 major markets?
• What will be the total number of patients with pollen allergy across the 8 major markets during the forecast period?
• What was the country-wise pollen allergy epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of pollen allergy patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of pollen allergy during the forecast period of 2026-2035?
• What are the currently available treatments for pollen allergy?
• What are the disease risks, signs, symptoms, and unmet needs of pollen allergy?

Scope of the Pollen Allergy Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of pollen allergy based on several factors.
• Pollen Allergy Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The pollen allergy report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Allergy Diagnostics and Therapeutics Market

Allergy Treatment Market